Qiagen (QGEN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Nov, 2026Executive summary
Q3 net sales rose 3% to $548 million, also up 3% CER and ahead of the prior 1–2% CER growth outlook; adjusted diluted EPS was $0.65, above the at-least-$0.62 CER outlook.
Pillar sales grew 7% CER to $415 million, partly offset by a 7% CER decline in the rest of the portfolio.
Financial highlights
Q3 operating income was $132 million, up 3%; adjusted operating income rose 6% to $167 million. Net income fell 19% to $106 million and diluted EPS fell 15% to $0.51.
9M net sales increased 2% to $1.575 billion; operating income declined 5% to $349 million, net income fell 13% to $277 million, and diluted EPS decreased 8% to $1.33.
9M adjusted diluted EPS rose 3% to $1.81; adjusted net income was $377 million, down 2%.
Outlook and guidance
2026 outlook was suspended, and financial guidance will not be provided while the pending EQT Private Equity transaction is ongoing.
The takeover offer is currently expected to close in mid-2027; no Q3 results conference call will be held.
Latest events from Qiagen
- 8% CER non-COVID growth lifted Q4 results; 2024 earnings face non-operating headwinds.QGEN
Q4 2023 - AI-driven automation, new product launches, and margin expansion drive growth amid strategic review.QGEN
Morgan Stanley 24th Annual Global Healthcare Conference - Automation, new launches, and strategic focus drive growth outlook amid leadership transition.QGEN
2026 Global Healthcare Conference - Q2 2026 sales and EPS exceeded expectations, driven by strong growth in core pillars.QGEN
Q2 2026 - New product launches and strategic review drive growth amid leadership transition and stable funding.QGEN
Leerink Global Healthcare Conference 2026 - Q1 2026 delivered 2% sales growth and solid profitability, with FY 2026 outlook reaffirmed.QGEN
Q1 2026 - Drives growth in sample prep with automation, high-value applications, and new tech leadership.QGEN
Status Update - 2028 plan targets ~7% sales CAGR, ≥31% margin, and $1B returns, led by innovation and efficiency.QGEN
CMD 2024 - Exceeded 2024 targets with strong recurring revenue, margin gains, and positive 2025 outlook.QGEN
Q4 2024